Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01035255 · ClinicalTrials.gov registry record · Phase 3
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8,442
- Enrollment target
NCT01035255 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 8,442 participants.
The verdict
NCT01035255, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8,442 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
Interventions
- DRUG LCZ696 200 mg BID
- DRUG Enalapril 10 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,442 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01035255
The ClinicalTrials.gov registry entry for NCT01035255 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8,442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LCZ696 200 mg BID is the first listed.
NCT01035255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01035255 about?
NCT01035255 is a clinical study titled "This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure". The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
What is the current status of trial NCT01035255?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8,442 participants. The study started on 2009-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01035255?
The interventions under investigation include: LCZ696 200 mg BID (DRUG), Enalapril 10 mg BID (DRUG).
Who is sponsoring clinical trial NCT01035255?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.